<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2d1 20170631//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article" dtd-version="1.2d1" specific-use="production" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MEDRXIV</journal-id>
<journal-title-group>
<journal-title>medRxiv</journal-title>
<abbrev-journal-title abbrev-type="publisher">medRxiv</abbrev-journal-title>
</journal-title-group>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1101/2021.04.18.21255684</article-id>
<article-version>1.1</article-version>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>Epidemiology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Effect of asymptomatic transmission and emergence time on multi-strain viral disease severity</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8543-9925</contrib-id>
<name><surname>Alizad-Rahvar</surname><given-names>A. R.</given-names></name>
<xref ref-type="aff" rid="a1">&#x002A;</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sadeghi</surname><given-names>M.</given-names></name>
<xref ref-type="author-notes" rid="n1">&#x2020;</xref>
</contrib>
<aff id="a1"><label>&#x002A;</label><institution>School of Biological Sciences, Institute for Research in Fundamental Sciences (IPM)</institution>, Tehran, <country>Iran</country></aff>
<aff id="a2"><label>&#x2020;</label><institution>;National Institute for Genetic Engineering and Biotechnology</institution>, Tehran, <country>Iran</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>&#x002A;</label>Corresponding authors&#x2019; email: <email>alizad@ipm.ir</email>,</corresp>
<fn id="n1"><label>&#x2020;</label><p><email>sadeghi@nigeb.ac.ir</email></p></fn>
</author-notes>
<pub-date pub-type="epub">
<year>2021</year>
</pub-date>
<elocation-id>2021.04.18.21255684</elocation-id>
<history>
<date date-type="received">
<day>18</day>
<month>4</month>
<year>2021</year>
</date>
<date date-type="rev-recd">
<day>18</day>
<month>4</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>23</day>
<month>4</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2021, Posted by Cold Spring Harbor Laboratory</copyright-statement>
<copyright-year>2021</copyright-year>
<license><license-p>The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.</license-p></license>
</permissions>
<self-uri xlink:href="21255684.pdf" content-type="pdf" xlink:role="full-text"/>
<abstract>
<title>Abstract</title>
<sec>
<title>Background</title>
<p>In a viral epidemic, the emergence of a novel strain with increased transmissibility (larger value of basic reproduction number <italic>R</italic><sub>0</sub>) sparks the fear that the increase in transmissibility is likely to lead to an increase in disease severity. It is required to investigate if a new, more contagious strain will be necessarily dominant in the population and resulting in more disease severity.</p></sec>
<sec>
<title>Methods</title>
<p>The impact of the asymptomatic transmission and the emergence time of a more transmissible variant of a multi-strain viral disease on the disease prevalence, disease severity, and the dominant variant in an epidemic was investigated by a proposed 2-strain epidemic model, called 2-SEICARD model, that is an extension of the SEIRD model.</p></sec>
<sec>
<title>Results</title>
<p>The simulation results showed that considering only <italic>R</italic><sub>0</sub>, is insufficient to predict the outcome of a new, more contagious strain in the population. A more transmissible strain with a high fraction of asymptomatic cases can substantially reduce the mortality rate. If the emergence time of the new strain is closer to the start of the epidemic, the new, more contagious variant has more chance to win the viral competition and be the dominant strain; otherwise, despite being more contagious, it cannot dominate previous strains.</p></sec>
<sec>
<title>Conclusions</title>
<p>Three factors of <italic>R</italic><sub>0</sub>, the fraction of asymptomatic transmission, and the emergence time of the new strain are required to correctly determine the prevalence, disease severity, and the winner of the viral competition.</p></sec>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>Asymptomatic</kwd>
<kwd>COVID-19</kwd>
<kwd>disease severity</kwd>
<kwd>dominant strain</kwd>
<kwd>emergence time</kwd>
<kwd>emergent strain</kwd>
<kwd>multi-strain virus</kwd>
</kwd-group>
<counts>
<page-count count="7"/>
</counts>
</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>The authors have declared no competing interest.</p></notes>
<notes notes-type="financial-disclosure">
<title>Funding Statement</title><p>No funding was received for this research.</p></notes>
<notes notes-type="disclosures">
<title>Author Declarations</title><p>I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.</p><p>Yes</p><p>The details of the IRB/oversight body that provided approval or exemption for the research described are given below:</p><p>This research does not need to comply with any ethical guidelines.</p><p>All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.</p><p>Yes</p><p>I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).</p><p>Yes</p><p>I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.</p><p>Yes</p></notes>
</notes>
</front>
<body>
<sec id="s1">
<label>I.</label>
<title>I<sc>ntroduction</sc></title>
<p>The emergence of the novel coronavirus strain in the UK, called SARS-CoV-2 VOC 202012/01 or B.1.1.7, was shocking because this novel variant could be up to about 70&#x0025; more transmissible than pre-existing variants of SARS-CoV-2<sup><xref ref-type="bibr" rid="c1">1</xref></sup>. This increased transmissibility can add between 0.4 and 0.7 to the basic reproduction number R<sub>0</sub>. This news sparked the fear that the increase in transmissibility is likely to lead to a large increase in hospitalization, intensive care unit (ICU) admission rate, and mortality. However, the studies about previous variants of SARS-CoV-2 showed that despite the rise of the lab-confirmed cases, the COVID-19 case fatality rate (CFR) declined, i.e., more transmissibility did not necessarily cause more severity<sup><xref ref-type="bibr" rid="c2">2</xref>,<xref ref-type="bibr" rid="c3">3</xref></sup>. Other studies in the UK and England showed that besides increasing the COVID-19 cases, the hospitalization rate, the ICU admission rate, and the CFR declined<sup><xref ref-type="bibr" rid="c4">4</xref>,<xref ref-type="bibr" rid="c5">5</xref></sup>. The preliminary explanation was the predominant shift towards positivity in younger age groups who have a better outcome. However, the analysis of German COVID-19 data<sup><xref ref-type="bibr" rid="c6">6</xref></sup>, which was reported by age categories, showed that the COVID-19 CFR declined across all age groups<sup><xref ref-type="bibr" rid="c7">7</xref></sup>. Interestingly, the older groups drove the overall reduction in CFR.</p>
<p>The public health authorities need to pinpoint the cause of this decline in the fatality rate in order to decide how to react against the newly emerged viral strains. The decision to fight blindly against a novel strain because of its increased transmissibility is not necessarily the most comprehensive and effective solution. We need to take other factors along with the transmissibility into account in our decision-making.</p>
<p>The spread of COVID-19 is an iceberg with the invisible part of being the asymptomatic transmission. The percent of asymptomatic cases who never experience COVID-19 symptoms remains uncertain. From about 20&#x0025; to 50&#x0025; of infected people are reported to be asymptomatic<sup><xref ref-type="bibr" rid="c8">8</xref>&#x2013;<xref ref-type="bibr" rid="c10">10</xref></sup>. In a study, 39&#x0025; of children aged 6-13 years tested positive for COVID-19 with no symptoms<sup><xref ref-type="bibr" rid="c11">11</xref></sup>. Different studies reported an insignificant difference in the upper respiratory viral load between symptomatic and asymptomatic cases<sup><xref ref-type="bibr" rid="c8">8</xref>,<xref ref-type="bibr" rid="c12">12</xref></sup>. Even a new study found that asymptomatic patients had higher SARS-CoV-2 viral loads than symptomatic cases<sup><xref ref-type="bibr" rid="c13">13</xref></sup>. Consequently, the asymptomatic infected people could play a significant driver role in the community spread of COVID-19. The results of a study demonstrated that both <italic>R</italic><sub>0</sub> and the proportion of asymptomatic transmissions were the main factors in controlling an infectious disease outbreak<sup><xref ref-type="bibr" rid="c14">14</xref></sup>.</p>
<p>In this study, we investigate the effect of the emergent viral strain on the total number of infected people and the illness severity by using epidemiological modeling. We will show that in an epidemic situation, the emergence time of the new strain and the relative <italic>R</italic><sub>0</sub> of the primary and the emergent strains determine the winner of the competition between two viral strains. Moreover, we will see that the disease severity and the mortality rate can be significantly influenced by the emergence time and the fraction of asymptomatic infectious cases of the emergent strain.</p>
</sec>
<sec id="s2">
<label>II.</label>
<title>M<sc>ethods</sc></title>
<p>For each viral strain, we use the extended version of the classic SEIRD epidemic model, called the SEICARD model, consisting of susceptible (S), exposed (in the latent period) (E), symptomatic infected (I), critically infected (C), asymptomatic infected (A), recovered (R), and dead (D) people. By paralleling two SEICARD models, we develop a 2-strain model, called 2-SEICARD, that describes the existence and competition of two viral variants in the population (<xref rid="fig1" ref-type="fig">Fig. 1</xref>). The index <italic>s</italic> = 1 or 2 in <italic>E</italic><sub><italic>s</italic></sub>, <italic>I</italic><sub><italic>s</italic></sub>, <italic>C</italic><sub><italic>s</italic></sub>, <italic>A</italic><sub><italic>s</italic></sub>, <italic>R</italic><sub><italic>s</italic></sub>, and <italic>D</italic><sub><italic>s</italic></sub> represents the infectious strain in each group. It is assumed that the emergence time of the second strain is <italic>T</italic><sub><italic>E</italic></sub> days after the emergence time of the primary one, which is day 0. Moreover, we assume that there is no viral superinfection, i.e., the reinfection or co-infection between variants does not occur. In other words, the recovered individuals are cross-immunized and are immune to the new variants.</p>
<fig id="fig1" position="float" fig-type="figure">
<label>Fig. 1.</label>
<caption><p>Schematic of the 2-SEICARD model. For simplicity, the lower branch, corresponding to the second strain, is not depicted, and it is denoted by <italic>EICARD</italic><sub>2</sub>. The <italic>EICARD</italic><sub>2</sub> branch appears in the model for <italic>t</italic> &#x2A7E; <italic>T</italic><sub><italic>E</italic></sub>.</p></caption>
<graphic xlink:href="21255684v1_fig1.tif"/>
</fig>
<p>The parameters of the 2-SEICARD model are explained in <xref ref-type="table" rid="tbl1">Table I</xref>. The ODE system of this 2-strain model is given by
<disp-formula id="eqn1">
<alternatives><graphic xlink:href="21255684v1_eqn1a.gif"/></alternatives>
</disp-formula>
<disp-formula id="eqn2">
<alternatives><graphic xlink:href="21255684v1_eqn1b.gif"/></alternatives>
</disp-formula>
<disp-formula id="eqn3">
<alternatives><graphic xlink:href="21255684v1_eqn1c.gif"/></alternatives>
</disp-formula>
<disp-formula id="eqn4">
<alternatives><graphic xlink:href="21255684v1_eqn1d.gif"/></alternatives>
</disp-formula>
<disp-formula id="eqn5">
<alternatives><graphic xlink:href="21255684v1_eqn1e.gif"/></alternatives>
</disp-formula>
<disp-formula id="eqn6">
<alternatives><graphic xlink:href="21255684v1_eqn1f.gif"/></alternatives>
</disp-formula>
<disp-formula id="eqn7">
<alternatives><graphic xlink:href="21255684v1_eqn1g.gif"/></alternatives>
</disp-formula>
for <italic>s</italic> = 1 and 2. Here, the total population is <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline1.gif"/></alternatives></inline-formula>. For simplicity, the natural birth and death rates are ignored in the model. To implement the emergence time <italic>T</italic><sub><italic>E</italic></sub>, we set all parameters of the second strain to zero for <italic>t</italic> &#x003C; <italic>T</italic><sub><italic>E</italic></sub>.</p>
<table-wrap id="tbl1" orientation="portrait" position="float">
<label>TABLE I</label>
<caption><p>E<sc>xplanation of the symbols of the</sc> 2-SEICARD <sc>model</sc>.</p></caption>
<graphic xlink:href="21255684v1_tbl1.tif"/>
</table-wrap>
<p>For each strain, the infection rates <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline2.gif"/></alternatives></inline-formula>, and <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline3.gif"/></alternatives></inline-formula> denote the probability of transmitting disease from <italic>I</italic><sub><italic>s</italic></sub>, <italic>C</italic><sub><italic>s</italic></sub>, or <italic>A</italic><sub><italic>s</italic></sub> to <italic>S</italic>, respectively. On the other hand, as <xref rid="fig1" ref-type="fig">Fig. 1</xref> shows, the outcome of each exposed person <italic>E</italic><sub><italic>s</italic></sub> could be <italic>A</italic><sub><italic>s</italic></sub>, <italic>I</italic><sub><italic>s</italic></sub>, <italic>C</italic><sub><italic>s</italic></sub>, and <italic>D</italic><sub><italic>s</italic></sub> with the probabilities of <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline4.gif"/></alternatives></inline-formula>, and <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline5.gif"/></alternatives></inline-formula>, respectively. By using the method of next-generation matrices<sup><xref ref-type="bibr" rid="c15">15</xref></sup>, we can obtain the following expression for the <italic>R</italic><sub>0</sub> of each strain
<disp-formula id="eqn8">
<alternatives><graphic xlink:href="21255684v1_eqn2.gif"/></alternatives>
</disp-formula>
where <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline6.gif"/></alternatives></inline-formula>, and <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline7.gif"/></alternatives></inline-formula> denote the reproduction number of each outcome, and <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline8.gif"/></alternatives></inline-formula> is obtained by their weighted sum. The weight of each outcome is the probability of its occurrence.</p>
<p>The values of different parameters used in the 2-SEICARD model are listed in <xref ref-type="table" rid="tbl1">Table I</xref>. In our modeling, we assume a wild animal population in which there is no isolation and social policy or restriction. Hence, we consider that all <italic>I</italic><sub><italic>s</italic></sub>, <italic>C</italic><sub><italic>s</italic></sub>, and <italic>A</italic><sub><italic>s</italic></sub> outcomes have the same probability of transmission; i.e., <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline9.gif"/></alternatives></inline-formula>. According to <xref ref-type="disp-formula" rid="eqn2">Eq. (2)</xref>, by considering <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline10.gif"/></alternatives></inline-formula> and the values of 0.13, 0.2, and 0.27 for all <italic>&#x03B2;</italic> values of strain 2, we have <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline11.gif"/></alternatives></inline-formula> and <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline12.gif"/></alternatives></inline-formula>, and 2.7, respectively.</p>
</sec>
<sec id="s3">
<label>III.</label>
<title>R<sc>esults and</sc> D<sc>iscussion</sc></title>
<p>In this section, we consider fixed parameters for the first strain in the 2-SEICARD model; i.e., <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline13.gif"/></alternatives></inline-formula> and <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline14.gif"/></alternatives></inline-formula>. Then, the emergent strain with different values of <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline15.gif"/></alternatives></inline-formula>, and 2.7 and <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline16.gif"/></alternatives></inline-formula> and 0.4 emerges at day <italic>T</italic><sub><italic>E</italic></sub>, where 0 &#x2A7D; <italic>T</italic><sub><italic>E</italic></sub> &#x2A7D; 100. In all the above scenarios, we study the effect of the emergent strain on the total number of infected cases and the mortality rate, as a measure of severity, from the beginning of the epidemic until we reach the endemic steady state. The total number of infected cases is <italic>N</italic> &#x2212; <italic>S</italic><sub>&#x221E;</sub>, where <italic>S</italic><sub>&#x221E;</sub> denotes the number of susceptible cases that have not been infected at all when the disease has gone. The mortality rate is the total proportion of deaths in the population due to infection.</p>
<sec id="s3a">
<label>A.</label>
<title>Effect of R<sub>0</sub> and T<sub>E</sub> on the total number of infections and the dominant strain</title>
<p>The simulation results show that the total number of infected cases does not vary with <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline17.gif"/></alternatives></inline-formula> for the fixed values of <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline18.gif"/></alternatives></inline-formula> and <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline19.gif"/></alternatives></inline-formula>. In other words, the values of <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline20.gif"/></alternatives></inline-formula> and <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline21.gif"/></alternatives></inline-formula> determine the total number of infected individuals during the epidemic spread. Provided that <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline22.gif"/></alternatives></inline-formula>, the emergent strain does not have any chance to compete with the primary strain and would become extinct immediately (see <xref rid="fig2" ref-type="fig">Fig. 2(A1)</xref>). In the case of <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline23.gif"/></alternatives></inline-formula>, the total number of infected cases with two strains remains the same as that in the case of spreading only the primary strain in the population with the same value of the basic reproduction number. Moreover, <xref rid="fig2" ref-type="fig">Fig. 2(A2)</xref> demonstrates that the total number of infected cases does not vary with the emergence time of the second strain, <italic>T</italic><sub><italic>E</italic></sub>. However, the later emergence of strain 2 results in less proportion of infection with this strain in the population. In contrast, <xref rid="fig2" ref-type="fig">Fig. 2(A3)</xref> depicts that the emergence of a more contagious strain <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline24.gif"/></alternatives></inline-formula> increases the total number of infected cases compared to the existence of only the primary strain. Furthermore, <xref rid="fig2" ref-type="fig">Fig. 2(A3)</xref> shows that the new, more contagious strain with larger value of <italic>R</italic><sub>0</sub> does not necessarily dominate in the population. In other words, <italic>R</italic><sub>0</sub> alone does not determine which virus wins the viral competition. Indeed, besides the values of <italic>R</italic><sub>0</sub>, the emergence time <italic>T</italic><sub><italic>E</italic></sub> also determines whether the new strain with more transmissibility dominates the primary one or not. The sooner emergence of the new, more contagious variant can make it dominant; otherwise, the primary strain remains dominant in the population.</p>
<fig id="fig2" position="float" fig-type="figure">
<label>Fig. 2.</label>
<caption><p>The effect of <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline26.gif"/></alternatives></inline-formula>, and <italic>T</italic><sub><italic>E</italic></sub> on the total number of infected cases (A1-A3) and the mortality rate (B1-B3). These figures indicate that increased transmissibility of the new emergent strain does not necessarily reflect more severity of the disease. <bold>A1-A3:</bold> The fraction of the population who are infected with strains 1 and 2 and the total percentage of the infected cases are depicted for three cases of <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline27.gif"/></alternatives></inline-formula>, and <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline28.gif"/></alternatives></inline-formula>. Also, these figures demonstrate that the emergent time of the new strain (<italic>T</italic><sub><italic>E</italic></sub>) should be considered to determine the winner of the viral competition. The legends of all figures are the same as those in Fig. A1. <bold>B1-B3</bold>: For <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline29.gif"/></alternatives></inline-formula> and <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline30.gif"/></alternatives></inline-formula>, these figures show the effect of increase in the fraction of asymptomatic cases of the emergent strain (<inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline31.gif"/></alternatives></inline-formula>, and 0.4 (B3)), on the mortality rate for different levels of transmissibility of the new variant (<inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline32.gif"/></alternatives></inline-formula>, and 2.7). The legends of all figures are the same as those in Fig. B1.</p></caption>
<graphic xlink:href="21255684v1_fig2.tif"/>
</fig>
</sec>
<sec id="s3b">
<label>B.</label>
<title>Effect of emergent strain on mortality rate</title>
<p>Our main question is that in the case of <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline25.gif"/></alternatives></inline-formula>, whether or not more infected cases increase similarly the mortality rate of the disease or not. To answer this question, consider the mortality rate in different circumstances in <xref rid="fig2" ref-type="fig">Figures 2(B1-B3)</xref>. These figures show concurrently the effect of the fraction of asymptomatic individuals infected with strain <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline33.gif"/></alternatives></inline-formula>, and the emergence time of the second strain, <italic>T</italic><sub><italic>E</italic></sub>, on the mortality rate for <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline34.gif"/></alternatives></inline-formula> and <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline35.gif"/></alternatives></inline-formula>, and 2.7. As we have discussed, if <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline36.gif"/></alternatives></inline-formula>, the emergent strain cannot compete with the primary strain, and hence, the mortality rate remains fixed for all values of <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline37.gif"/></alternatives></inline-formula>, equal to the mortality rate of the primary strain alone. Hence, in these figures, although blue curves are corresponding to the 2-strain scenario, they also represent the mortality rate of the primary strain alone.</p>
<p>As we expected, provided that <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline38.gif"/></alternatives></inline-formula> and <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline39.gif"/></alternatives></inline-formula>, the mortality rate remains the same as that of the primary strain alone. On the other hand, as <xref rid="fig2" ref-type="fig">Fig. 2(B1)</xref> depicts, if both strains have a similar proportion of asymptomatic cases, i.e., <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline40.gif"/></alternatives></inline-formula>, the mortality rate increases with the emergence of a more contagious strain <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline41.gif"/></alternatives></inline-formula>. In this case, the sooner that the new strain emerges, the more in the mortality rate increases. However, as <xref rid="fig2" ref-type="fig">Figures 2(B2-B3)</xref> show, the increase in <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline42.gif"/></alternatives></inline-formula> can reduce the mortality rate for <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline43.gif"/></alternatives></inline-formula>. For large values of <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline44.gif"/></alternatives></inline-formula>, although a more contagious strain emerges, it can make the mortality rate less than that before the emergence (<xref rid="fig2" ref-type="fig">Fig. 2(B3)</xref>). Interestingly, for large values of <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline45.gif"/></alternatives></inline-formula>, the emergent strain with higher <italic>R</italic><sub>0</sub> decreases the mortality rate more. In other words, more transmissibility does not reflect necessarily more severity, and both <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline46.gif"/></alternatives></inline-formula> and <inline-formula><alternatives><inline-graphic xlink:href="21255684v1_inline47.gif"/></alternatives></inline-formula> values should be considered to correctly determine the effect of the more transmissible new strain on the viral disease severity.</p>
</sec>
</sec>
<sec id="s4">
<label>IV.</label>
<title>C<sc>onclusion</sc></title>
<p>In this study, we investigated the impact of the asymptomatic transmission and the emergence time of the new, more contagious viral strain on the disease prevalence, disease severity, and the dominant variant in an epidemic. Our results demonstrated that being an emergent strain with more transmissibility, i.e., having a larger basic reproduction number <italic>R</italic><sub>0</sub>, compared to previous variants, does not necessarily lead to more severity or mean that the new variant will dominate in the population. Indeed, when a new strain with a larger basic reproduction number emerges, it will increase the number of infected cases in the population. However, the creation of more severe outcomes depends on the fraction of asymptomatic transmissions. If a large proportion of infections, due to the new variant, do not show any symptom, they can even reduce the mortality rate in the population. Moreover, provided that the emergence time of the new strain is closer to the start of the epidemic, the new, more contagious variant has more chance to win the viral competition and be the dominant strain; otherwise, despite being more contagious, it cannot dominate previous strains.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability">
<title>Data Availability</title>
<p>No data is available.</p>
</sec>
<ack>
<title>A<sc>cknowledgement</sc></title>
<p>The authors would like to thank A. Kalirad for constructive discussion that contributed to the development of this research.</p>
</ack>
<ref-list>
<title>R<sc>eferences</sc></title>
<ref id="c1"><label>[1]</label><mixed-citation publication-type="other"><string-name><surname>Davies</surname> <given-names>NG</given-names></string-name>, <string-name><surname>Barnard</surname> <given-names>RC</given-names></string-name>, <string-name><surname>Jarvis</surname> <given-names>CI</given-names></string-name>, <string-name><surname>Kucharski</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Munday</surname> <given-names>J</given-names></string-name>, <string-name><surname>Pearson</surname> <given-names>CAB</given-names></string-name>, <etal>et al.</etal> <source>Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England. medRxiv</source>. <year>2020</year>.</mixed-citation></ref>
<ref id="c2"><label>[2]</label><mixed-citation publication-type="website"><collab>SARS-CoV-2 Variants</collab>;. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/don/31-december-2020-sars-cov2-variants/">www.who.int/csr/don/31-december-2020-sars-cov2-variants/</ext-link>.</mixed-citation></ref>
<ref id="c3"><label>[3]</label><mixed-citation publication-type="website"><collab>Why do COVID death rates seem to be falling?</collab>;. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.nature.com/articles/d41586-020-03132-4">www.nature.com/articles/d41586-020-03132-4</ext-link>.</mixed-citation></ref>
<ref id="c4"><label>[4]</label><mixed-citation publication-type="other"><string-name><surname>Howdon</surname> <given-names>D</given-names></string-name>, <string-name><surname>Oke</surname> <given-names>J</given-names></string-name>, <string-name><surname>Heneghan</surname> <given-names>C.</given-names></string-name> <source>COVID-19: Declining Admissions to Intensive Care Units</source>;. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.cebm.net/covid-19/covid-19-declining-admissions-to-intensive-care-units">www.cebm.net/covid-19/covid-19-declining-admissions-to-intensive-care-units</ext-link>.</mixed-citation></ref>
<ref id="c5"><label>[5]</label><mixed-citation publication-type="other"><string-name><surname>Howdon</surname> <given-names>D</given-names></string-name>, <string-name><surname>Heneghan</surname> <given-names>C.</given-names></string-name> <source>The Declining Case Fatality Ratio in England</source>;. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.cebm.net/covid-19/the-declining-case-fatality-ratio-in-england">www.cebm.net/covid-19/the-declining-case-fatality-ratio-in-england</ext-link>.</mixed-citation></ref>
<ref id="c6"><label>[6]</label><mixed-citation publication-type="website"><collab>RKI COVID19</collab>;. Available from: <ext-link ext-link-type="uri" xlink:href="https://npgeo-corona-npgeo-de.hub.arcgis.com/datasets/dd4580c810204019a7b8eb3e0b329dd6_0/data">https://npgeo-corona-npgeo-de.hub.arcgis.com/datasets/dd4580c810204019a7b8eb3e0b329dd60/data</ext-link>.</mixed-citation></ref>
<ref id="c7"><label>[7]</label><mixed-citation publication-type="website"><string-name><surname>Oke</surname> <given-names>J</given-names></string-name>, <string-name><surname>Howdon</surname> <given-names>D</given-names></string-name>, <string-name><surname>Heneghan</surname> <given-names>C.</given-names></string-name> <source>Declining COVID-19 Case Fatality Rates across all ages: analysis of German data</source>;. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.cebm.net/covid-19/declining-covid-19-case-fatality-rates-across-all-ages-analysis-of-german-data">https://www.cebm.net/covid-19/declining-covid-19-case-fatality-rates-across-all-ages-analysis-of-german-data</ext-link>.</mixed-citation></ref>
<ref id="c8"><label>[8]</label><mixed-citation publication-type="journal"><string-name><surname>Ra</surname> <given-names>SH</given-names></string-name>, <string-name><surname>Lim</surname> <given-names>JS</given-names></string-name>, <string-name><given-names>Kim</given-names> <surname>Gu</surname></string-name>, <string-name><surname>Kim</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Jung</surname> <given-names>J</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>SH</given-names></string-name>. <article-title>Upper respiratory viral load in asymptomatic individuals and mildly symptomatic patients with SARS-CoV-2 infection</article-title>. <source>Thorax</source>. <year>2021</year>;<volume>76</volume>(<issue>1</issue>):<fpage>61</fpage>&#x2013;<lpage>63</lpage>.</mixed-citation></ref>
<ref id="c9"><label>[9]</label><mixed-citation publication-type="journal"><string-name><surname>Gudbjartsson</surname> <given-names>DF</given-names></string-name>, <string-name><surname>Helgason</surname> <given-names>A</given-names></string-name>, <string-name><surname>Jonsson</surname> <given-names>H</given-names></string-name>, <string-name><surname>Magnusson</surname> <given-names>OT</given-names></string-name>, <string-name><surname>Melsted</surname> <given-names>P</given-names></string-name>, <string-name><surname>Norddahl</surname> <given-names>GL</given-names></string-name>, <etal>et al.</etal> <article-title>Spread of SARS-CoV-2 in the Icelandic Population</article-title>. <source>New England Journal of Medicine</source>. <year>2020</year>;<volume>382</volume>(<issue>24</issue>):<fpage>2302</fpage>&#x2013;<lpage>2315</lpage>.</mixed-citation></ref>
<ref id="c10"><label>[10]</label><mixed-citation publication-type="journal"><string-name><surname>Byambasuren</surname> <given-names>O</given-names></string-name>, <string-name><surname>Cardona</surname> <given-names>M</given-names></string-name>, <string-name><surname>Bell</surname> <given-names>K</given-names></string-name>, <string-name><surname>Clark</surname> <given-names>J</given-names></string-name>, <string-name><surname>McLaws</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Glasziou</surname> <given-names>P.</given-names></string-name> <article-title>Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: Systematic review and meta-analysis</article-title>. <source>Journal of the Association of Medical Microbiology and Infectious Disease Canada</source>. <year>2020</year>;<volume>5</volume>:<fpage>223</fpage>&#x2013;<lpage>234</lpage>.</mixed-citation></ref>
<ref id="c11"><label>[11]</label><mixed-citation publication-type="website"><string-name><surname>Hurst</surname> <given-names>JH</given-names></string-name>, <string-name><surname>Heston</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Chambers</surname> <given-names>HN</given-names></string-name>, <string-name><surname>Cunningham</surname> <given-names>HM</given-names></string-name>, <string-name><surname>Price</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Suarez</surname> <given-names>L</given-names></string-name>, <etal>et al.</etal> <article-title>Severe Acute Respiratory Syndrome Coronavirus 2 Infections Among Children in the Biospecimens from Respiratory Virus-Exposed Kids (BRAVE Kids) Study</article-title>. <source>Clinical Infectious Diseases. 2020 11</source>. Available from: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/cid/ciaa1693">https://doi.org/10.1093/cid/ciaa1693</ext-link>.</mixed-citation></ref>
<ref id="c12"><label>[12]</label><mixed-citation publication-type="website"><string-name><surname>Cereda</surname> <given-names>D</given-names></string-name>, <string-name><surname>Tirani</surname> <given-names>M</given-names></string-name>, <string-name><surname>Rovida</surname> <given-names>F</given-names></string-name>, <string-name><surname>Demicheli</surname> <given-names>V</given-names></string-name>, <string-name><surname>Ajelli</surname> <given-names>M</given-names></string-name>, <string-name><surname>Poletti</surname> <given-names>P</given-names></string-name>, <etal>et al.</etal> <article-title>The early phase of the COVID-19 outbreak in Lombardy, Italy</article-title>. <source>arXiv</source>. <year>2020</year>. Available from: <ext-link ext-link-type="uri" xlink:href="https://arxiv.org/abs/2003.09320">https://arxiv.org/abs/2003.09320</ext-link>.</mixed-citation></ref>
<ref id="c13"><label>[13]</label><mixed-citation publication-type="other"><string-name><surname>Hasanoglu</surname> <given-names>I</given-names></string-name>, <string-name><surname>Korukluoglu</surname> <given-names>G</given-names></string-name>, <string-name><surname>Asilturk</surname> <given-names>D</given-names></string-name>, <string-name><surname>Cosgun</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Kalem</surname> <given-names>AK</given-names></string-name>, <string-name><surname>Altas</surname> <given-names>AB</given-names></string-name>, <etal>et al.</etal> <article-title>Higher viral loads in asymptomatic COVID-19 patients might be the invisible part of the iceberg</article-title>. <source>Infection</source>. <year>2020</year> <month>Nov</month>.</mixed-citation></ref>
<ref id="c14"><label>[14]</label><mixed-citation publication-type="journal"><string-name><surname>Fraser</surname> <given-names>C</given-names></string-name>, <string-name><surname>Riley</surname> <given-names>S</given-names></string-name>, <string-name><surname>Anderson</surname> <given-names>RM</given-names></string-name>, <string-name><surname>Ferguson</surname> <given-names>NM</given-names></string-name>. <article-title>Factors that make an infectious disease outbreak controllable</article-title>. <source>Proceedings of the National Academy of Sciences</source>. <year>2004</year>;<volume>101</volume>(<issue>16</issue>):<fpage>6146</fpage>&#x2013;<lpage>6151</lpage>. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.pnas.org/content/101/16/6146">https://www.pnas.org/content/101/16/6146</ext-link>.</mixed-citation></ref>
<ref id="c15"><label>[15]</label><mixed-citation publication-type="journal"><string-name><surname>Diekmann</surname> <given-names>O</given-names></string-name>, <string-name><surname>Heesterbeek</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Roberts</surname> <given-names>MG</given-names></string-name>. <article-title>The construction of next-generation matrices for compartmental epidemic models</article-title>. <source>J R Soc Interface</source>. <year>2010</year> <month>Jun</month>;<volume>7</volume>(<issue>47</issue>):<fpage>873</fpage>&#x2013;<lpage>885</lpage>.</mixed-citation></ref>
</ref-list>
</back>
</article>